Filed Pursuant to Rule
424(b)(3)
S-1 Registration Statement
SEC
File No. 333-148727
PROSPECTUS SUPPLEMENT
NO. 2
Prospectus Supplement dated March 18,
2008
to Prospectus declared
effective on January 28, 2008
PURE BIOSCIENCE
This prospectus supplement dated
March 31, 2008, or this prospectus supplement, supplements and amends our
prospectus dated January 28, 2008, relating to the offer and sale by the selling
stockholders identified in such prospectus of up to 2,264,749 shares of our common stock.
We refer to our prospectus dated January 28, 2008 as the prospectus. This
prospectus supplement includes our attached current report on Form 8-K filed with the
Securities and Exchange Commission on March 31, 2008.
You should read this prospectus
supplement in conjunction with the prospectus. This prospectus supplement is qualified by
reference to the prospectus, except to the extent that the information contained in this
prospectus supplement supersedes the information contained in the prospectus. This
prospectus supplement is not complete without, and may not be utilized except in
connection with, the prospectus, including any amendments or additional supplements
thereto. Capitalized terms used in this prospectus supplement but not otherwise defined
herein shall have the meanings given to such terms in the prospectus.
Our common stock is quoted on the OTC
Bulletin Board under the symbol PURE and as of April 2, 2008 will be quoted on
the NASDAQ Capital Market continuing under the symbol PURE.
The last reported sales price per
share of our common stock, as reported by the OTC Bulletin Board on March 28, 2008, was
$5.64.
Investing in our common stock
involves a high degree of risk. See Risk Factors beginning on page 4 of the
prospectus.
Neither the Securities and
Exchange Commission nor any state securities commission has approved or disapproved of
these securities or determined if this prospectus supplement or the prospectus is truthful
or complete. Any representation to the contrary is a criminal offense.
The date of this
prospectus supplement is March 31, 2008.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
March 31, 2008
Date of Report (Date of earliest event reported):
PURE
BIOSCIENCE
(Exact name of registrant as specified in charter)
|
|
|
California
(State or other jurisdiction of incorporation)
|
|
33-0530289
(IRS Employer Identification No.)
|
1725 Gillespie
Way, El Cajon, California 92020
(Address of principal executive offices)
(619) 586
8600
Registrant’s telephone number, including area code:
Check the appropriate box below if
the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the
registrant under any of the following provisions:
[ ] Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange
Act (17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under
the Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under
the Exchange Act (17 CFR 240.13e-4(c))
Item 7.01.
Regulation FD Disclosure
Item 8.01. Other Events.
On March 31, 2008, PURE Bioscience
announced today that its application for listing of its common stock has been approved by
The NASDAQ Stock Market. PURE Bioscience anticipates that its common stock will begin
trading on The NASDAQ Capital Market at the opening of the market on Wednesday April 2,
2008. The stock will trade under the symbol PURE. The Press Release is
attached as Exhibit 99.1 to this Current Report on Form 8-K.
The information in this 8-K
(including Exhibit 99.1) is being furnished and shall not be deemed
filed for purposes of Section 18 of the Securities Exchange Act of 1934,
as amended (the Exchange Act) or otherwise subject to the liabilities of that
section, nor shall it be deemed incorporated by reference in any filing under the
Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the
date of this report, except as shall be expressly set forth by specific reference in such
filing.
This Current Report on Form 8-K
contains forward-looking statements that do not convey historical information,
but relate to predicted or potential future events, such as statements of our plans,
strategies and intentions. These statements can often be identified by the use of
forward-looking terminology such as believe, expect,
intend, may, will, should, or
anticipate or similar terminology. All statements other than statements of
historical facts included in this Current Report on Form 8-K are forward-looking
statements. All forward-looking statements speak only as of the date of this Current
Report on Form 8-K. Except for PUREs ongoing obligations to disclose material
information under the federal securities laws, PURE undertakes no obligation to update or
revise any forward-looking statements, whether as a result of new information, future
events or otherwise. In addition to the risks and uncertainties of ordinary business
operations and conditions in the general economy and the markets in which Pure competes,
the forward-looking statements of PURE contained in this Current Report on Form 8-K are
also subject various risks and uncertainties, including those set forth in Risk
Factors, in PUREs Annual Report on Form 10-KSB for the fiscal year ended JULY
31, 2007, and in its subsequent filings made with the Securities and Exchange Commission.
Item 9.01. Financial
Statements and Exhibits
(d)
|
The
following exhibits are filed with this report:
|
|
Exhibit
Number
|
Description
|
|
99.1
|
Press
Release dated March 31, 2008
|
SIGNATURES
Pursuant to the requirements of the
Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed
on its behalf by the undersigned, thereunto duly authorized.
PURE BIOSCIENCE
Dated: March 31, 2008
/s/ Michael L. Krall
Michael L. Krall, Chief
Executive Officer
Exhibit 99.1
|
|
NEWS
|
|
PURE Bioscience
Announces Approval to List on The NASDAQ Stock Market
San Diego, CA March 31,
2008:
PURE Bioscience (OTCBB: PURE) announced today that its application for listing
of its common stock has been approved by The NASDAQ Stock Market. PURE Bioscience
anticipates that its common stock will begin trading on The NASDAQ Capital Market at the
opening of the market on Wednesday April 2, 2008. The stock will trade under the symbol
PURE.
Returning to the NASDAQ Stock
Market has been a primary goal for us this year, said Michael L. Krall, President
and Chief Executive Officer of PURE Bioscience. We expect NASDAQs electronic
multiple market maker structure to provide our company with enhanced exposure and
liquidity, and afford our investors the best prices, the fastest execution, and the lowest
cost per trade. As the worlds largest electronic stock market, NASDAQ promotes
innovation and attracts leading growth companies from a diverse group of sectors. PURE
Bioscience certainly fits that description, and we look forward to being a part of The
NASDAQ Stock Market.
We are thrilled that PURE
Bioscience has chosen to relist their stock on NASDAQ, said Bob McCooey, Senior Vice
President of New Listings and Capital Markets of The NASDAQ OMX Group, Inc. PURE
Bioscience joins the worlds largest exchange company that spans six
continents. We look forward to supporting PURE Bioscience and its shareholders as
they make their transition to NASDAQ.
About PURE Bioscience
PURE
Bioscience develops and markets technology-based bioscience products that provide
solutions to numerous global health challenges, including Staph (MRSA). PUREs
proprietary high efficacy/low toxicity bioscience technologies, including its silver
dihydrogen citrate-based antimicrobials, represent innovative advances in diverse markets
and lead todays global trend toward industry and consumer use of green products
while providing competitive advantages in efficacy and safety. Patented SDC is an
electrolytically generated source of stabilized ionic silver which formulates well with
other compounds. As a platform technology, SDC is distinguished from competitors in the
marketplace because of its superior efficacy, reduced toxicity and the inability of
bacteria to form a resistance to it. PURE is headquartered in El Cajon, California (San
Diego metropolitan area). Additional information on PURE is available at
www.purebio.com
.
About NASDAQ
®
The
NASDAQ Stock Market, a national exchange owned and operated by the NASDAQ OMX Group,
Inc., is the largest U.S. electronic stock market. With approximately 3,200 companies, it
lists more companies and, on average, its systems trade more shares per day than any
other U.S. market. NASDAQ is home to companies that are leaders across all areas of
business including technology, retail, communications, financial services,
transportation, media and biotechnology.
For more information about NASDAQ,
visit the NASDAQ Web site at
www.nasdaq.com
or the NASDAQ Newsroom(SM) at
www.nasdaq.com/newsroom
.
This press release includes
statements that may constitute forward-looking statements, usually containing
the words believe, estimate, project,
expect or similar expressions. These statements are made pursuant to the safe
harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking
statements inherently involve risks and uncertainties that could cause actual results to
differ materially from the forward-looking statements. Factors that would cause or
contribute to such differences include, but are not limited to, acceptance of the
Companys current and future products and services in the marketplace, the ability of
the Company to develop effective new products and receive regulatory approvals of such
products, competitive factors, dependence upon third-party vendors, and other risks
detailed in the Companys periodic report filings with the Securities and Exchange
Commission. By making these forward-looking statements, the Company undertakes no
obligation to update these statements for revisions or changes after the date of this
release.
|
|
|
|
Investor Contact:
Paul G. Henning, Vice President
Cameron Associates
(212) 554-5462
paul@cameronassoc.com
|
Media Contact:
Karen Sparks, Mentus
858-455-5500 x 275
karen@mentus.com
|
PURE Bioscience (PK) (USOTC:PURE)
Historical Stock Chart
From Jun 2024 to Jul 2024
PURE Bioscience (PK) (USOTC:PURE)
Historical Stock Chart
From Jul 2023 to Jul 2024